| Sargramostim (GM-CSF) + PD-1 (NCT04703426) | Dana-Farber Cancer Institute | 2021-04-16 |
| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy (NCT03719131) | Emory University | 2019-06-05 |
| Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors (NCT03385486) | Taiga Biotechnologies, Inc. | 2019-06-02 |
| TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (NCT04059224) | Universitair Ziekenhuis Brussel | 2019-01-28 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (NCT03200847) | University of Colorado, Denver | 2017-10-31 |
| Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (NCT02676869) | Immutep Australia Pty. Ltd. | 2016-04-01 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NCT02306850) | St. Louis University | 2015-01-01 |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma (NCT01875653) | Lisata Therapeutics, Inc. | 2014-10-01 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (NCT02073123) | NewLink Genetics Corporation | 2014-07-01 |
| Interferon Toxicities in Melanoma Treatment (NCT02794636) | Bristol-Myers Squibb | 2014-05-01 |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations (NCT01726738) | UNC Lineberger Comprehensive Cancer Center | 2013-04-04 |
| Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma (NCT01376713) | Medical University of Vienna | 2011-06-01 |
| Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma (NCT01026051) | Mannkind Corporation | 2010-10-01 |
| Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma (NCT01107665) | University of California, Irvine | 2010-08-01 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma (NCT00945269) | Fred Hutchinson Cancer Center | 2009-07-01 |
| VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00450255) | National Cancer Institute (NCI) | 2007-06-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT01851408) | National Cancer Institute (NCI) | 2006-04-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT00349206) | National Cancer Institute (NCI) | 2006-04-01 |
| Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery (NCT00217542) | National Cancer Institute (NCI) | 2005-07-01 |
| Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00119249) | National Cancer Institute (NCI) | 2005-06-01 |
| Tanespimycin in Treating Patients With Stage III-IV Melanoma (NCT00087386) | National Cancer Institute (NCI) | 2004-06-01 |
| Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma (NCT00082875) | National Cancer Institute (NCI) | 2004-03-01 |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers (NCT00074308) | National Cancer Institute (NCI) | 2003-10-01 |
| Decitabine in Treating Patients With Advanced Solid Tumors (NCT00030615) | National Cancer Institute (NCI) | 2001-12-01 |
| Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg (NCT00003789) | National Cancer Institute (NCI) | 1999-03-01 |
| Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma (NCT00003646) | Vical | 1998-08-01 |
| Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma (NCT00003647) | Vical | 1998-07-01 |
| Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma (NCT00019890) | National Cancer Institute (NCI) | |